NCT04465591 TROPOnin FRAGMentation in Myocardial Injury Study
| NCT ID | NCT04465591 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Turku |
| Condition | Acute Myocardial Infarction Type 1 |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2020-04-02 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2020-04-02 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Troponin T (TnT) is a part of the troponin protein complex that principally exists in cardiac and skeletal muscle cells and is widely used as diagnostic biomarker for myocardial injury and, thus, myocardial infarction (MI). Elevated TnT levels can, however, be observed in the presence of other clinical conditions such as heart failure, sepsis and kidney failure and the contemporary high-sensitivity TnT test may yield false positive results when performing diagnostics for suspected MI in these patients. Recent data have demonstrated that in the presence of MI, TnT gradually undergoes fragmentation into smaller fragments. It has been suggested that in the presence of e.g. chronic kidney disease or physical exercise the released TnT is predominantly in the form of smaller fragments. However, the clinical significance of TnT fragmentation is unknown and, thus, we sought to investigate the prevalence of fragmentation of TnT in different patient cohorts.
Eligibility Criteria
Inclusion Criteria: * Troponin T fragmentation sample collected from a recruited patient. Exclusion Criteria: * Age \<18
Contact & Investigator
Juhani K Airaksinen, MD, PhD
PRINCIPAL INVESTIGATOR
University of Turku
Frequently Asked Questions
Who can join the NCT04465591 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myocardial Infarction Type 1. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04465591 currently recruiting?
Yes, NCT04465591 is actively recruiting participants. Contact the research team at juhani.airaksinen@tyks.fi for enrollment information.
Where is the NCT04465591 trial being conducted?
This trial is being conducted at Turku, Finland, Zurich, Switzerland.
Who is sponsoring the NCT04465591 clinical trial?
NCT04465591 is sponsored by University of Turku. The principal investigator is Juhani K Airaksinen, MD, PhD at University of Turku. The trial plans to enroll 1,500 participants.